Uncertainty Looms Over Immunovant's Future As Batoclimab Faces Dim Prospects Seeking Alpha, 06 Mar 2023 Follow Summary Immunovant's lead drug, batoclimab, is one of many FcRn antagonists, either approved or in development, for the…